论文部分内容阅读
根据高原缺氧作用特点配制高原Ⅱ（ＫＹ－Ⅱ）号药（中西复方），在动物实验证明具有降低缺氧动物的氧耗量、延长活存时间和提高活存率的基础上，选用１８～２５岁健康男性青年２３名，随机分为高原Ⅰ号（ＫＹ－Ⅰ，安慰剂，ｎ＝１２）和ＫＹ－Ⅱ号药组，减压至模拟４０００～５０００ｍ高原低氧环境连续生活７２ｈ，采用双盲法，观察ＫＹ－Ⅱ号药预防急性高原反应的效果。结果表明：ＫＹ－Ⅱ号药组急性高原反应发病人数少于ＫＹ－Ⅰ号组；按照Ｊｏｈｎｓｏｎ等计分法进行症状量化分析，在模拟５０００ｍ高原时．ＫＹ－Ⅱ号药组的得分显著低于ＫＹ－Ⅰ号组（Ｐ＜０．０５），重度急性高原反应人数少于ＫＹ－Ⅰ号组（Ｐ＜０．０５）；症状反应的轻重与动脉血氧饱和度（ＳａＯ２）呈显著负相关（ｒ＝－０．９９８，Ｐ＜０．０５）；两组间心缩间期（ＳＴＩ）各参数变化，在统计学上无显著意义（Ｐ＞０．０５）。上述结果表明，ＫＹ－Ⅱ号药具有减轻急性高原反应症状，降低其发病率的效果。
According to the characteristics of hypoxia on the plateau, the preparation of highland Ⅱ (KY-Ⅱ) medicine (compound Chinese and western medicine) was prepared. On the basis of animal experiments demonstrating that it can reduce the oxygen consumption, prolong the survival time and increase the survival rate of anoxic animals, Twenty-three healthy male volunteers aged 25 to 25 years were randomly divided into two groups: control group (KY-Ⅰ, placebo, n = 12) and KY- Double-blind method was used to observe the effect of KY-II on preventing acute altitude sickness. The results showed that the incidence of acute altitude sickness in KY-Ⅱ drug group was less than that in KY-Ⅰ group, and the symptom quantification analysis was performed according to Johnson’s score method and so on. The score of KY-Ⅱ was significantly lower than that of KY-Ⅰ (P <0.05), and the number of patients with severe acute altitude was less than that of KY-Ⅰ (P0.05). The severity of symptoms and arterial (R = -0.998, P <0.05). The parameters of systolic interval (STI) between the two groups had no statistical significance (P> 0.05). The above results indicate that KY-II has the effect of alleviating symptoms and reducing the incidence of acute altitude sickness.